Maxim analyst Jason Kolbert remains bullish on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the oncology drug maker just made waves signing a licensed agreement deal for Zoprtex, a new peptide-conjugated chemical entity designed to treat endometrial cancer. This follows in a series of agreements Aeterna has recently made in China and Asia, with Zoptrex now being licensed for Israel and Palestinian territories. Kolbert reiterates a Buy rating, with a price target of $11, marking a 215% increase from where shares last closed.
Zoptrex matters to AEZS investors, because as Kolbert mentions, it could very well be on the brink of a New Drug Application filing come first quarter of 2017. With crucial data results that could prove Zoptrex might more effectively kill cancer and be a safer treatment with less toxicity and no trace of cardiotoxicity, the analyst sees potential for the program with minimal risk. This, in Kolbert’s eyes, is precisely “what makes Zoptrex unique,” in the fact “that it is not just another dox,” as in J&J’s ovarian cancer drug Doxil.
Kolbert finds, “As pivotal data nears, Aeterna is now shifting towards commercialization. With a lack of data (data trough period) for many companies in 2016, we see Aeterna as an exception with two pivotal studies reading out in the short term (<six months). As such we continue to see AEZS as an exceptional value in the space.” With Zoptrex on the rise, both in the Holy Land and abroad, Kolbert feels confident in this investment.
As usual, we suggest you take any analyst’s notes with a grain of salt. They often successfully move stock prices, but it is always wise to take everything in context. According to TipRanks, Jason Kolbert is ranked #4,004 out of 4,085 analysts. With a success rate of 29%, Kolbert loses an average of 14% in his annual returns.
TipRanks analytics exhibit AEZS stock is a Moderate Buy. Of the 2 analysts who offered recommendations in the last 3 months on Aeterna, both rate a Buy. The 12-month average price target is $11.50, marking a 232% upside.